MiNK Therapeutics, Inc. (INKT)
$10.23-2.85%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $51M
- Beta
- 0.47
- P/E (TTM)
- -4.28
- Short % float
- 4.15%
- Days to cover
- 3.1
- SI change
- -13.2%
- 1W
- -12.56%
- 1M
- -14.54%
- vs SPY 1W
- -12.43%
- vs SPY 1M
- -17.04%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 12
- GROWTH
- 36
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC50.1%
REV YoY-
ROE83.4%
EPS YoY-
ROA-118.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.28
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-3.66
P/FCF-
EV/EBITDA-3.52
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.23
ND/EBITDA-
BETA0.47
Company news
FAQ
- What is LOPJLB’s current signal on INKT?
- LOPJLB’s latest quantitative signal on MiNK Therapeutics, Inc. (INKT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is INKT in?
- MiNK Therapeutics, Inc. (INKT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MiNK Therapeutics, Inc. (INKT) do?
- MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in imm…